COMPANY:

ANGLE

"ANGLE plc...is delighted to announce that it has entered a collaboration with Myriad Genetics, Inc...Under the terms of the agreement, blood samples from cancer patients will be processed by ANGLE's research and development team utilising the Parsortix® system for the capture and harvest of intact cancer cells for downstream molecular analysis. Results for this analysis will compare CTC-DNA with matched patient tissue samples using Myriad Genetics' existing tissue-based assay."

"ANGLE plc...is delighted to announce that it has successfully completed the AstraZeneca development work for both the Parsortix-based Androgen Receptor ('AR') assay and the DNA damage response ('DDR') assay for the detection of micronuclei in CTCs as a measure of DNA damage...Both the developed assays (AR and DDR) have been approved for use by AstraZeneca and we are currently using the assays to test blood samples from patients. These developments put ANGLE in the position to be able to execute large scale clinical trials for AstraZeneca. In addition, ANGLE is working to progress discussions in other areas where we believe AstraZeneca could benefit from adopting CTC analysis."

"ANGLE...is delighted to announce the publication of novel research by Professor Dario Marchetti's team at the University of New Mexico Comprehensive Cancer Center, United States. The study used the Parsortix® system to investigate CTC and B cell* clusters in clinical and pre-clinical models of melanoma brain metastasis, and their ability to target additional organs during the spread of cancer ("metastasis of metastasis")."

"ANGLE plc…is delighted to announce new, successful results for the Company's dual circulating tumour DNA (ctDNA) and CTC-DNA workflow using, for the first time, an end-to-end Illumina solution for analysis…In the study, ctDNA was first isolated from the plasma and CTCs were isolated and harvested using the Parsortix^® system from a single blood tube taken from 27 lung cancer patients. CTCs and ctDNA were then analysed using Illumina's customised 79 gene lung cancer panel with NGS completed on the Illumina NextSeq 2000 platform."

"ANGLE plc...is pleased to announce the presentation of an independent study, reporting on a novel, Parsortix®-based human epidermal growth factor receptor 2 (HER2) workflow at the prominent San Antonio Breast Cancer Symposium being held from 10 to 13 December 2024...The findings, published by Weill Cornell Medicine, corroborate ANGLE's own findings from its HER2 assay development programme, and provide a semi-automated solution which may help to accelerate adoption of CTC-based HER2 tests. HER2 status is known to change in a significant proportion of breast cancer patients over time, so a minimally invasive, real-time assay is needed for dynamic HER2 assessment to enable targeted treatment selection and detection of emerging treatment resistance or progression."

"ANGLE plc...announce its participation at the European Association for Cancer Research (EACR) Liquid Biopsies Conference being held in Lyon, France from 12 to 14 November 2024."

"ANGLE plc...is pleased to announce the publication of new data at the American Association for Cancer Research (AACR) Special Conference in Cancer Research in San Diego, US from 13 to 16 November 2024...ANGLE is presenting a poster entitled the 'Development of a scoring system to classify HER2 protein expression in Circulating Tumor Cells through immunofluorescence following isolation using Parsortix® instruments' and reports on progress of the Company's co-development programme with BioView."

"ANGLE plc...is pleased to announce the publication of new data at the American Association for Cancer Research (AACR) Special Conference in Cancer Research, Liquid Biopsy: From Discovery to Clinical Implementation, in San Diego, US from 13 to 16 November 2024."

"ANGLE plc...is pleased to announce its participation at the European Association for Cancer Research (EACR) Liquid Biopsies Conference being held in Lyon, France from 12 to 14 November 2024...ANGLE presented two posters at the EACR Liquid Biopsies Conference...This poster presentation reports on the utility of combining ANGLE's Parsortix® system for CTC capture with the Portrait®+ CTC staining kit for CTC detection and phenotypic characterisation...This proof-of-concept study demonstrates that using amplitude-based multiplexing with QIAGEN's Qiacuity dPCR system can increase the number of genes that can be assessed simultaneously in a Parsortix-enriched CTC sample."

"ANGLE plc...is pleased to announce the publication of research investigating the dual analysis of CTCs and circulating tumour DNA (ctDNA) in non-small cell lung cancer (NSCLC), undertaken by the National and Kapodistrian University of Athens. Researchers used the Parsortix® system to isolate and harvest CTCs from 30 patients with EGFR-mutated NSCLC that were undergoing treatment with osimertinib (TAGRISSO: AstraZeneca). Osimertinib is an EGFR inhibitor with annual revenues of c. US$6.7 billion, growing at c. 16% per annum. Both CTCs and ctDNA were analysed using a range of molecular techniques which enabled the identification of mutations, methylation, gene expression and amplification."

"ANGLE plc...announce the publication of research investigating a panel of known prostate cancer gene transcripts in CTCs, undertaken by the Comprehensive Cancer Center at the Medical University of Vienna...Researchers used the Parsortix®system to isolate and harvest CTCs from 38 localised and metastatic prostate cancer patients. CTCs were then analysed using a range of molecular techniques which enabled multiple biomarkers to be simultaneously analysed."

"ANGLE plc...is pleased to announce the publication of the 100th peer-reviewed journal article using the Parsortix® system for the isolation, harvest and analysis of CTCs...The journal article is published by researchers from a leading international referral centre for the treatment and study of cancer, the Fondazione IRCCS - Istituto Nazionale dei Tumori Di Milano (Italy)."